Anxiety Disorders and Depression Treatment Market By Product Type, Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, SRIs, SNRIs, TeCAs, TCAs, Others), By Distribution Channel, and Geography
Anxiety Disorders and Depression Treatment Market Size was valued at US$ 14.2 billion in 2023 and is poised to grow at a CAGR of 3.8% from 2024-2030. Anxiety is a disorder that differs from normal feelings of nervousness or anxiousness. It involves excessive anxiety. Anxiety is a normal reaction to stress. For a patient with anxiety disorder, the anxiety does not lessen but can get worse over a period of time. As per the American Psychiatric Association, Anxiety disorders are the most common of mental disorders and affect nearly 30 percent of adults at some point in their lives. The feelings can interfere with daily activities. There are various kinds of anxiety disorders such as social anxiety disorder and panic disorder.
Study Period
2024-2030Base Year
2023CAGR
3.8%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Increase in the prevalence of anxiety disorder and depression is majorly driving the growth of the anxiety disorders and depression treatment market. According to the World Health Organization (WHO), in 2017, over 300 million people of all ages globally are suffering from depression, wherein 800,000 people die due to suicide, of which, anxiety disorders and depression are a prime cause.
The rising demand for the antidepressants can be attributed to the growth of the market. Growing geriatric population along with mental disorders are adding fuel for the growth of the anxiety disorders and depression treatment market. However, the factors such as patent expiry of the drugs and adoption of the other treatment options such as herbal treatment are expected to hinder the growth of the market. The growing generic drugs are likely to restrain the growth of the anxiety disorders and depression treatment market.
Geographically, global anxiety disorders and depression treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North Americaanxiety disorders and depression treatment market is the dominant market when compared with that of the other regional markets.
According to the National Alliance on Mental Illness, Anxiety disorders are the most common mental health concern in the United States. An estimated 40 million adults in the United States (18%) have an anxiety disorder. Meanwhile, approximately 8% of children and teenagers experience an anxiety disorder. Most people develop symptoms before age 21.
According to the Mental Health America, in 2014, 1 in every 5 adults have a mental health condition and the condition is observed to be worsening at rapid rates in youth. The Asia Pacific anxiety disorders and depression treatment market is expected to show a luxurious growth over the forecasted period.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 14.2 billion |
|
Market CAGR |
3.8% |
|
By Product Type |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Anxiety disorders and depression treatment market size was valued at US$ 14.2 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024-2030
The anxiety disorders and depression treatment market key players are Eli Lilly and Company (U.S) Lundbeck A/S (Denmark) AstraZeneca (UK) Merck and Company, Inc. (U.S) Johnson and Johnson (U.S) Sanofi-Aventis (France) GlaxoSmithKline plc (UK) Pfizer, Inc. (U.S)
The anxiety disorders and depression treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1.Executive Summary |
| 2.Global Anxiety Disorders And Depression Treatment Market Introduction |
| 2.1.Global Anxiety Disorders And Depression Treatment Market - Taxonomy |
| 2.2.Global Anxiety Disorders And Depression Treatment Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3.Global Anxiety Disorders And Depression Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Anxiety Disorders And Depression Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Anxiety Disorders And Depression Treatment Market By Product Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. MAOIs (Monoamine Oxidase inhibitors) |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Atypical Antipsychotics |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Benzodiazepines |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Anticonvulsants |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Beta-Blockers |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. SRIs (Selective Serotonin Reuptake Inhibitors) |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. TeCAs (Tetracyclic Antidepressants) |
| 5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. TCAs (Tricyclic Antidepressants) |
| 5.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 5.10. Others |
| 5.10.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.10.3. Market Opportunity Analysis |
| 6.Global Anxiety Disorders And Depression Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Online Pharmacies |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Anxiety Disorders And Depression Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Anxiety Disorders And Depression Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.MAOIs (Monoamine Oxidase inhibitors) |
| 8.1.2.Atypical Antipsychotics |
| 8.1.3.Benzodiazepines |
| 8.1.4.Anticonvulsants |
| 8.1.5.Beta-Blockers |
| 8.1.6.SRIs (Selective Serotonin Reuptake Inhibitors) |
| 8.1.7.SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) |
| 8.1.8.TeCAs (Tetracyclic Antidepressants) |
| 8.1.9.TCAs (Tricyclic Antidepressants) |
| 8.1.10.Others |
| 8.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacies |
| 8.2.2.Online Pharmacies |
| 8.2.3.Others |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Anxiety Disorders And Depression Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.MAOIs (Monoamine Oxidase inhibitors) |
| 9.1.2.Atypical Antipsychotics |
| 9.1.3.Benzodiazepines |
| 9.1.4.Anticonvulsants |
| 9.1.5.Beta-Blockers |
| 9.1.6.SRIs (Selective Serotonin Reuptake Inhibitors) |
| 9.1.7.SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) |
| 9.1.8.TeCAs (Tetracyclic Antidepressants) |
| 9.1.9.TCAs (Tricyclic Antidepressants) |
| 9.1.10.Others |
| 9.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacies |
| 9.2.2.Online Pharmacies |
| 9.2.3.Others |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Anxiety Disorders And Depression Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.MAOIs (Monoamine Oxidase inhibitors) |
| 10.1.2.Atypical Antipsychotics |
| 10.1.3.Benzodiazepines |
| 10.1.4.Anticonvulsants |
| 10.1.5.Beta-Blockers |
| 10.1.6.SRIs (Selective Serotonin Reuptake Inhibitors) |
| 10.1.7.SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) |
| 10.1.8.TeCAs (Tetracyclic Antidepressants) |
| 10.1.9.TCAs (Tricyclic Antidepressants) |
| 10.1.10.Others |
| 10.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacies |
| 10.2.2.Online Pharmacies |
| 10.2.3.Others |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Anxiety Disorders And Depression Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.MAOIs (Monoamine Oxidase inhibitors) |
| 11.1.2.Atypical Antipsychotics |
| 11.1.3.Benzodiazepines |
| 11.1.4.Anticonvulsants |
| 11.1.5.Beta-Blockers |
| 11.1.6.SRIs (Selective Serotonin Reuptake Inhibitors) |
| 11.1.7.SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) |
| 11.1.8.TeCAs (Tetracyclic Antidepressants) |
| 11.1.9.TCAs (Tricyclic Antidepressants) |
| 11.1.10.Others |
| 11.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacies |
| 11.2.2.Online Pharmacies |
| 11.2.3.Others |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Anxiety Disorders And Depression Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.MAOIs (Monoamine Oxidase inhibitors) |
| 12.1.2.Atypical Antipsychotics |
| 12.1.3.Benzodiazepines |
| 12.1.4.Anticonvulsants |
| 12.1.5.Beta-Blockers |
| 12.1.6.SRIs (Selective Serotonin Reuptake Inhibitors) |
| 12.1.7.SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) |
| 12.1.8.TeCAs (Tetracyclic Antidepressants) |
| 12.1.9.TCAs (Tricyclic Antidepressants) |
| 12.1.10.Others |
| 12.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacies |
| 12.2.2.Online Pharmacies |
| 12.2.3.Others |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Eli Lilly and Company |
| 13.2.2.Lundbeck A/S |
| 13.2.3.AstraZeneca |
| 13.2.4.Merck and Company, Inc. |
| 13.2.5.Johnson and Johnson |
| 13.2.6.Sanofi-Aventis |
| 13.2.7.GlaxoSmithKline plc |
| 13.2.8.Pfizer, Inc. |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
